MedTrace Logo

Effect of Thiazolidinedione Treatment Vascular Risk Markers

NCT00571506 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2009-12-09

No results posted yet for this study

Summary

The purpose of this study is to examine the effects of two diabetes medications, rosiglitazone and pioglitazone, on markers of vascular disease in subjects with type 2 diabetes.

Conditions

  • Diabetes Mellitus, Type 2
  • Vascular Diseases

Interventions

DRUG

Rosiglitazone

Rosiglitazone 4 mg tablets by mouth daily for 3 months

DRUG

Pioglitazone

Pioglitazone 30 mg tablet by mouth once daily

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Amy M. Franks, Pharm.D. · University of Arkansas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00571506 on ClinicalTrials.gov